DOSAGE AND ADMINISTRATION
The medicine is indicated for adult patients only, it is not recommended during pregnancy and lactation.
Currently, there are two forms of Vinpotropile® release: capsules (vinpocetine 5 mg and piracetam 400 mg) and tablets (vinpocetine 10 mg and piracetam 800 mg). Dosage: 1 - 2 capsules / tablets, 2 - 3 times per day. Course: 3 - 8 weeks. Before cancellation, the dose should be gradually reduced. For the full information on the administration, please refer to the official description.
SIDE EFFECTS & OVERDOSE
The side effects include urticaria or dermatitis, gastralgia, heartburn and diarrhea. Other side effects often include tachycardia, extrasystole, angina pectoris, and hot flashes. Possible side effects in the central nervous system include headache, hyperkinesis, excitation, depression, increased sweating and extrapyramidal disorders.
Overdose can be manifested in the form of increased severity of side effects. For more information, please refer to the description.
It is strictly prohibited to use the drug along with alcohol-containing substances. It is possible to drink alcohol one day before or after using the drug for men, and two days before or after - for women. If the drug is used as a course treatment, a patient can start drinking alcohol after one month from the end of the full course.
Vinpotropile® is a combination drug. It is able to improve cerebral blood flow due to the active substance Vinpocetine and it can exert a nootropic effect through Piracetam, which is another active substance. This drug was developed in cooperation with N. Yakhno the Academician of the Russian Academy of Sciences. The optimal dosage of the components in Vinpotropile® and their proven synergy at the molecular level provide good tolerance and allow the drug to be used in a wide range of daily dosages.
Characteristics of the active components of the drug:
Vinpocetine was first isolated from Lesser Periwinkle plant by a Hungarian chemist Csaba Szántay. It was found that the compound had a cerebral-flow enhancing and neuroprotective effect. Over the last decades, it has been extensively studied and now is used in Eastern Europe for the treatment of cerebrovascular disorders and age-related memory impairment.
Piracetam is a nootropic drug, historically the first and main representative of this group of drugs. It was first synthesized in the 1960s by Corneliu E. Giurgea. In Russia and Europe, Piracetam is widely used in clinical practice for the treatment of many neurological, psychiatric and other diseases.
Active components of Vinpotropile® have the following properties:
- Hemorheological Action (Reducing Blood Viscosity): Vinpocetine and Piracetam reduce the ability of platelets to aggregate, thus decreasing blood coagulation. They increase the ability of erythrocytes to deform and pass through the blood vessels.
- Blood Supply to the Brain: Vinpocetine improves blood supply to ischemic sections. Piracetam dilates the brain blood vessels.
- Brain Cell Metabolism: Vinpocetine binds to specific proteins, normalizing the membrane potential of cells, i.e. increasing ATP synthesis. Piracetam alters the properties of the mitochondrial membrane, contributing to better permeability of the active substances.
- Antioxidant action: Vinpocetine reduces the concentration of reactive oxygen species and blocks lipid peroxidation (formation of free radicals). Piracetam increases the resistance of the membranes to oxidative stress (exposure to free radicals).
It activates antioxidant system enzymes.
- Neuroprotective Action: Vinpocetine and Piracetam prevent the pathological death of neurons (apoptosis). Piracetam also enhances the utilization of oxygen in the brain. It has a membrane stabilizing effect, and stimulates alternative mechanisms for maintaining energy metabolism.
- Improving Memory and Cognitive Function: Vinpocetine activates the locus coeruleus fibers (a group of neurons diffusely distributed throughout the cerebral cortex and involved in the regulation of cognitive brain functions). Piracetam acts on substances that potentiate neurogenesis, improving or restoring cognitive functions.
Due to the combination composition, Vinpotropile® has a complex pathogenetic effect on the development factors of vascular cognitive impairment. Vinpotropile® has a multifactorial effect and reduces the number of drugs taken. This significantly increases the effectiveness of the cognitive deficit therapy.
- Circulatory failure of the brain, dizziness, migraines;
- Parkinsonism of the vascular origin;
- Intoxication, alcoholism;
- Psycho-organic syndrome with signs of adynamia and asthenia, etc.
- Filimonov et al (2007) Vinpotropile in the treatment of cerebral vascular diseases https://www.ncbi.nlm.nih.gov/pubmed/18689000
- A Kuznetsov, V Daminov (2007) Implication of vinpotropile in the treatment of patients with cerebral stroke https://www.ncbi.nlm.nih.gov/pubmed/18927980
- O Vorobeva, E Tamarova (2010) Efficacy of vinpotropile in the therapy of initial signs of cerebrovascular pathology https://www.ncbi.nlm.nih.gov/pubmed/21183904